iCardiac Technologies, Inc. has announced that it has entered into a multi-year research alliance with Pfizer Inc. to develop and validate advanced ECG-based cardiac safety biomarkers utilizing the COMPAS technology platform.
The COMPAS technology was developed at the University of Rochester within its Heart Research Follow-Up Program (HRFUP), a premier group of electro cardiology researchers focused on the ventricular repolarization process of the heart, and exclusively licensed to iCardiac.
The aim of the research alliance is the further development of iCardiac's COMPAS platform and advanced ECG markers for use in the safety testing of in-development and on-market drugs, and includes a cross-licensing arrangement by which iCardiac will receive rights to ECG analysis technologies developed within Pfizer.
Under the terms of the agreement, iCardiac and Pfizer will collaborate on a research program comprised of a series of studies, including retrospective and prospective ECG data analyses.
iCardiac will receive an equity investment and technology license payment, plus research and development funding over the term of the alliance.
iCardiac will retain commercial rights to the validated technology platform and new biomarkers for future application in cardiac safety clinical trials and technologies.
"We are extremely pleased that Pfizer has partnered with iCardiac in further developing iCardiac's suite of ECG-based biomarkers and its COMPAS platform technology for advancing the field of cardiac safety testing in pharmaceutical research and development," said Alexandra Latypova, co-founder and executive vice president of iCardiac Technologies.
"It is an honor to be working with Pfizer's scientific team and its leadership in furthering the important work of improving the way pharmaceutical products are developed and tested for safety."